Results 241 to 250 of about 39,319 (333)

Double Strike in Chronic Lymphocytic Leukemia-The Combination of BTK and BCL2 Inhibitors in Actual and Future Clinical Practice. [PDF]

Int J Mol Sci
Zygmunciak P, Dancewicz H, Stróżna K, Błażowska O, Bieliński K, Robak T, Puła B.   +6 more
europepmc   +1 more source

Ibrutinib enhances the bias of T cell responses towards staphylococcal superantigens sustaining inflammation in chronic lymphocytic leukaemia. [PDF]

Front Immunol
Tantoush F, Allsup D, Naylor-Adamson L, Voncken F, Caserta S.   +4 more
europepmc   +1 more source

“Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia”

, 2017
Maurizio Cavallari, Maria Ciccone, Simonetta Falzoni, Francesco Cavazzini, Luca Formigaro, Francesco Di Virgilio, Antonella Rotola, Gian Matteo Rigolin, Antonio Cuneo   +8 more
openalex   +1 more source

Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study. [PDF]

Blood Adv
Brown JR, Li J, Eichhorst BF, Lamanna N, O'Brien SM, Tam CS, Qiu L, Huang R, Shi Y, Idoine A, Salmi T, Cohen AC, Shadman M.   +12 more
europepmc   +1 more source

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. [PDF]

, 2018
Bence-Bruckler, I, Caballero, D, Cho, S-G, Dreyling, M, Goldberg, J, Henninger, T, Hess, G, Jerkeman, M, Joao, C, Jurczak, W, Offner, F, Rule, S, Rusconi, C, Thieblemont, C, Trneny, M, Vermeulen, J, Witzens-Harig, M, Zhou, W   +17 more
core   +3 more sources

Commentary on "real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies". [PDF]

BMC Pharmacol Toxicol
Namdar AB, Keikha M.
europepmc   +1 more source

The role of Janus kinase signaling in graft-versus-host disease and graft versus leukemia [PDF]

, 2018
Choi, Jaebok, DiPersio, John F, Schroeder, Mark A, Staser, Karl   +3 more
core   +2 more sources

Ibrutinib outperforms FCR in CLL [PDF]

Nature Reviews Clinical Oncology, 2019
openaire   +2 more sources

Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review. [PDF]

Target Oncol
Miklos DB, Riedell PA, Bokun A, Chavez JC, Schuster SJ.   +4 more
europepmc   +1 more source

Incidence of pneumonia among bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis of clinical trials. [PDF]

Ann Hematol
Mahadevia H, Ponvilawan B, Shrestha A.
europepmc   +1 more source